Cereno Scientific Q2 FY26 loss widens to SEK 30.53 million; net sales flat at no revenue

Reuters2026/08/26 06:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cereno Scientific posted a wider Q2 loss after financial items of SEK 30.53 million, while net sales stayed at no revenue.
Earnings per share slipped to SEK -0.10 before dilution, improving to SEK -0.09 after dilution.
Cash and bank balance fell to SEK 38.98 million, with the equity/assets ratio down 3.2 percentage points to 43.2%.
Board approved a directed share issue of SEK 60 million at SEK 5.1 per share; first EPIMODE Phase IIb site for CS1 activated.
CS014 Phase I PK bridging study completed dosing; topline results expected in Q3 2026, supporting a planned Phase IIb start in Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cereno Scientific AB published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cereno Scientific Q2 FY26 loss widens to SEK 30.53 million; net sales flat at no revenue

You may also like

Crypto prices